Medicine Overview of Rabe 20mg Capsule
Introduction
Rabe is a medicine that reduces the amount of acid produced in your stomach. It is used for treating acid-related diseases of the stomach and intestine such as heartburn, acid reflux, peptic ulcer disease, and some other stomach conditions associated with excessive acid production. Rabe is also used to prevent stomach ulcers and acidity that may be seen with the prolonged use of pain-killers. It belongs to a class of medicines known as proton pump inhibitors (PPIs). This medicine should be taken one hour before a meal, preferably in the morning. The dose will depend on your underlying condition and
Uses of Rabe
- Gastroesophageal reflux disease (Acid reflux)
- Peptic ulcer disease
Side effects of Rabe
Common
- Diarrhea
- Dizziness
- Flatulence
- Headache
- Nausea
- Sore throat
- Stomach pain
- Vomiting
How to use Rabe
Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Rabe is to be taken empty stomach.
How Rabe works
Rabe is a proton pump inhibitor (PPI). It works by reducing the amount of acid in the stomach which helps in relief of acid related indigestion and heartburn.
What if you forget to take Rabe?
If you miss a dose of Rabe, take it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular schedule. Do not double the dose.
Quick Tips
-
It is a well-tolerated medicine and provides relief for a long time.
-
Avoid eating late at night or before bedtime.
-
Inform your doctor if you get watery diarrhea, fever or stomach pain that does not go away.
-
Inform your doctor if you do not feel better after taking it for 14 days as you may be suffering from some other problem that needs attention.
-
Long-term use of Rabe can cause weak bones and a deficiency of minerals such as magnesium. Take adequate dietary intake of calcium and magnesium or their supplements as prescribed by your doctor.
-
Consult your doctor right away if you develop decreased urination, edema (swelling due to fluid retention), lower back pain, nausea, fatigue, and rash or fever. These could be signs of a kidney problem.
Brief Description
Indication
Peptic ulcer disease, H. pylori infection, Gastro-oesophageal reflux disease, Paediatric GERD
Administration
Administer with or without meals
Adult Dose
Oral Gastro-oesophageal reflux disease Adult: 20 mg daily for 4-8 wk. Maintenance: 10 or 20 mg/day. All doses to be taken once in the morning. Zollinger-Ellison syndrome Adult: Initially, 60 mg once in the morning, adjusted to max dose of 120 mg/day if needed. Daily doses >100 mg should be given in 2 divided doses. Peptic ulcer Adult: 20 mg once in the morning for 4-8 wk (duodenal ulcer) or for 6-12 wk (gastric ulcer). H.pylori infection Adult: 1-wk triple therapy: 20 mg bid combined w/ clarithromycin 500 mg bid and amoxicillin 1 g bid or combined w/ clarithromycin 250
Child Dose
Delayed-release capsule (sprinkles)
<1 year: Safety and efficacy not established
1-11 years (<15 kg): 5 mg PO qDay 30 minutes before a meal, for up to 12 weeks; may increase to 10 mg/day if inadequate response
1-11 years (>15 kg): 10 mg PO qDay 30 minutes before a meal, for up to 12 weeks
<1 year: Safety and efficacy not established
1-11 years (<15 kg): 5 mg PO qDay 30 minutes before a meal, for up to 12 weeks; may increase to 10 mg/day if inadequate response
1-11 years (>15 kg): 10 mg PO qDay 30 minutes before a meal, for up to 12 weeks
Gastroesophageal Reflux Disease
Delayed-release tablet
<12 years: Safety and efficacy not established
>12 years: 20 mg PO qDay for up to 8 weeks
Renal Dose
Renal impairment: No dosage adjustment needed.
Contraindication
Rabeprazole is contraindicated in patients with known hypersensitivity to Rabeprazole, other PPIs or to any component of the formulation.
Mode of Action
Rabeprazole is a PPI that suppresses gastric acid secretion by inhibiting H+/K+ ATPase at the secretory surface of the gastric parietal cell.
Precaution
Gastric malignancy should be ruled out. Severe hepatic impairment. Pregnancy and lactation. Monitoring Parameters Monitor Mg levels prior to initiation and periodically during prolonged use.
Lactation
Risk Summary
Lactation studies have not been conducted to assess presence in human milk, effects on breastfed infant, or effects on milk production; drug is present in rat milk; development and health benefits of breastfeeding should be considered along with mother’s clinical need for therapy and any potential adverse effects on breastfed infant from drug or from underlying maternal condition
Side Effect
1-10%
Headache (2-10%),Constipation (2%),Diarrhea (2-5%),Flatulence (3%),Pain (3%),Pharyngitis (3%),Abdominal pain (4%)
Headache (2-10%),Constipation (2%),Diarrhea (2-5%),Flatulence (3%),Pain (3%),Pharyngitis (3%),Abdominal pain (4%)
<1%
Agitation,Agranulocytosis,Alopecia,Anemia,Angioedema,Chest pain,Delirium,Erythema,Hypokalemia,Hypomagnesemia,Hyponatremia,Jaundice,Leukocytosis,Leukopenia,Migraine,Osteoporosis related fracture,Rhabdomyolysis,Stevens-Johnson syndrome,Sudden death,Toxic epidermal necrolysis,Abnormal taste
Pregnancy Category Note
Risk Summary There are no available human data in pregnant women to inform drug associated risk; background risk of major birth defects and miscarriage for indicated populations are unknown; however, background risk in U.S. general population of major birth defects is 2-4% and of miscarriage is 15- 20% of clinically recognized pregnancies; no evidence of adverse developmental effects were seen in animal reproduction studies with rabeprazole administered during organogenesis at 13 and 8 times human area under plasma concentration-time curve (AUC) at recommended dose for GERD, in rats and rabbits, respectively; Changes in bone morphology were observed in offspring of
Interaction
May decrease serum concentration of ketoconazole, itraconazole and clopidogrel. Increased risk of hypomagnesaemia w/ diuretics and digoxin. May increase prothrombin time and INR of warfarin. May increase plasma concentration of saquinavir and methotrexate. Decreased serum levels w/ sucralfate.
Potentially Fatal: May decrease plasma concentrations and pharmacological effects of rilpivirine and atazanavir.
Potentially Fatal: May decrease plasma concentrations and pharmacological effects of rilpivirine and atazanavir.
Reviews
Clear filtersThere are no reviews yet.